Canaccord Initiates HITK, MAPP, PTX at Buy

by Juan Lopez, Benzinga Staff Writer
January 5, 2012 8:29 AM | 13 seconds read |
Canaccord Genuity has initiated coverage on the following companies: Hi-Tech Pharmacal HITK Buy, $45 PT MAP Pharmaceuticals MAPP Buy, $24 PT Pernix Therapeutics PTX Buy, $15 PT
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetInitiationPre-Market OutlookAnalyst RatingsCanaccord GenuityHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!